With immunology and inflammatory disorders affecting between 7.6 and 9.4% of the population globally,1 we’re here to help you get your next innovative product to market with maximum speed and efficiency. After all, with such a large burden on society, we understand how important it is. Our broad range of global and local knowledge in inflammatory and allergy disease research is second to none. We have an extensive global network of sites along with strong clinical research teams. It means we’re the people you want to work with if you’re serious about moving the field of immunology forward.

Read how we can help you move the field of immunology forward.

This area poses particular challenges for patient recruitment, as the sheer number of immunology clinical studies going on at any one time can make it hard to find the numbers needed. Additionally, the difficulty in managing endpoints that are often complex in nature means it’s essential to be working with people who have the right experience to ensure the data you get is the data you need. That’s where we come in.

Our experience includes:

Ankylosing spondylitis, bursitis, celiac disease, gout, idiopathic thrombocytopenic purpura, immune deficiency, inflammatory bowel disease, osteoarthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis (adult and juvenile), sarcoidosis, scleroderma, Sjögren’s syndrome, systemic lupus erythematosus (SLE), systemic sclerosis, tendonitis, vasculitis.

Our work in practice


A customer asked us to take care of their Phase III clinical program for the first targeted drug for SLE. The trial included more than 1,800 patients at more than 220 sites globally, with complex study endpoints to manage.


To cope with the high number of patients to enroll and the complex endpoints, we selected experienced SLE sites from our database, which resulted in a worldwide cooperation with sites in 33 countries across all regions. We also put much emphasis on CRA training, to make sure our staff would be able to respond effectively to the specific challenges of the project. 


Recruitment for the SLE clinical trial was accomplished on time, allowing us to complete the study without delay and obtain quality data for our customer. This ultimately resulted in the successful registration of the drug.

Phase III

Subjects 1,800

Sites 220

Let us help you get your next innovative product to market with maximum speed and efficiency.


1 Cooper GS, Bynum, MLK and Somers EC. J Autoimmun. 2009 ; 33(3-4): 197–207. doi:10.1016/j.jaut.2009.09.008.

a This is an estimate of INC Research studies from the last five years that are completed or scheduled to complete for this therapy area.